Given Slc7a11 deletion is safe (108), and considering it does not compromise antitumor immune response in vivo (109), xCT inhibition is now posed as a promising therapeutic approach for pancreatic cancer. Here, SLC7A11 is linked to familial pancreatic carcinoma.